NASDAQ: SWAVShockwave Medical Inc Stock
$194.33-0.16 (-0.08%)
Updated Sep 25, 2023
SWAV Price
$194.33
Fair Value Price
$201.72
Market Cap
$7.14B
52 Week Low
$172.50
52 Week High
$320.54
P/E
28.79x
P/B
11.58x
P/S
16.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$616.59M
Earnings
$243.90M
Gross Margin
86.9%
Operating Margin
25.34%
Profit Margin
39.6%
Debt to Equity
0.28
Operating Cash Flow
$161M
Beta
1.3
Next Earnings
Nov 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A
SWAV Overview
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SWAV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SWAV ($194.33) is undervalued by 3.67% relative to our estimate of its Fair Value price of $201.72 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SWAV ($194.33) is not significantly undervalued (3.67%) relative to our estimate of its Fair Value price of $201.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SWAV is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SWAV due diligence checks available for Premium users.
Be the first to know about important SWAV news, forecast changes, insider trades & much more!
SWAV News
Valuation
SWAV fair value
Fair Value of SWAV stock based on Discounted Cash Flow (DCF)
Price
$194.33
Fair Value
$201.72
Undervalued by
3.67%
SWAV ($194.33) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SWAV ($194.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SWAV is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SWAV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
28.79x
Industry
49.2x
Market
14.28x
SWAV is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SWAV is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
SWAV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.58x
Industry
3.53x
SWAV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SWAV's financial health
Profit margin
Revenue
$180.2M
Net Income
$28.9M
Profit Margin
16%
SWAV's Earnings (EBIT) of $156.25M... subscribe to Premium to read more.
Interest Coverage Financials
SWAV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$786.6M
Liabilities
$169.7M
Debt to equity
0.28
SWAV's short-term assets ($456.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SWAV's short-term assets ($456.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SWAV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$39.7M
Investing
-$83.8M
Financing
-$95.8M
SWAV's operating cash flow ($160.62M)... subscribe to Premium to read more.
Debt Coverage Financials
SWAV vs Medical Device Stocks
Shockwave Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.